Fusen Pharmaceutical Co Ltd is a China-based company principally engaged in the provision of Shuanghuanglian series cold medicines. The Company is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The Company's main products include small volume injections, oral liquids, tablets, capsules and granules. The Company distributes its products mainly in domestic market.

Employees

1,005

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
17/06/26	0.9800 $	-4.85%	167,000
16/06/26	1.030 $	-0.96%	46,000
15/06/26	1.040 $	0.00%	0
12/06/26	1.040 $	-0.95%	101,000
11/06/26	1.050 $	0.00%	15,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Delayed Hong Kong S.E. Other stock markets 10:38:21 17/06/2026 +04			5-day change	1st Jan Change
0.9800 ^HKD	-4.85%		-6.67%	+22.50%

06-16	Fusen Pharma Unit's Piracetam Injection Gains Marketing Approval in China	MT
05-11	Fusen Pharma Units Gets China Nod to Market Post-Operative Pain Drug	MT

Market Cap	657M 761M 97.2M 83.77M 77.14M 72.43M 136M 9.19B 137M 912M 355M 4.5B 365M 357M 15.6B	P/E Ratio 2024	-2.95x	P/E Ratio 2025	-45.1x
Enterprise Value	879M 1.02B 130M 112M 103M 96.89M 182M 12.29B 184M 1.22B 475M 6.02B 488M 478M 20.87B	EV / Sales 2024	2.83x	EV / Sales 2025	2.76x
Free-Float	26.11%	Yield 2024 *	-	Yield 2025	-

06-16	Fusen Pharma Unit's Piracetam Injection Gains Marketing Approval in China	MT
05-11	Fusen Pharma Units Gets China Nod to Market Post-Operative Pain Drug	MT
05-11	Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited a wholly-owned subsidiary of Fusen Pharmaceutical Company Limited Announces Approval of Lornoxicam for Injection	CI
04-30	Fusen Pharmaceutical Company Limited Auditor Raises 'Going Concern' Doubt	CI
04-27	Fusen pharmaceutical says dydrogesterone tablet receives marketing approval from PRC NMPA	RE
04-27	Fusen Pharmaceutical Unit Gets Marketing Nod for Progesterone Deficiency Drug in China	MT
04-27	Jiaheng Zhuhai Hengqin Pharmaceutical Technology Company Limited Announces Approval of Dydrogesterone Tablet for Marketing	CI
04-17	Fusen Pharmaceutical receives NMPA approval to market glucosamine sulfate capsule in PRC	RE
03-31	Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-29	Fusen Pharmaceutical obtains approval for marketing from NMPA as phosphate supplement	RE
12-29	Fusen Pharmaceutical Unit Gets China Nod for Phosphate Supplement Marketing	MT
12-29	Jiaheng (Zhuhai Heng) Pharmaceutical Technology Company Limited Obtains Approval for Marketing from the National Medical Products Administration of the PRC as a Phosphate Supplement	CI
12-12	Henan Fusen Pharmaceutical Company Limited Receives Notification of Approval of Consistency Evaluation of Nicardipine Hydrochloride Injection	CI

28/04/22	Fusen Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, RE-APPOINTMENT OF AUDITORS, DECLARATION OF FINAL DIVIDEND, AMENDMENTS TO THE MEMORANDUM AND THE ARTICLES, ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING	PU
11/09/20	Fusen Pharmaceutical : Interim Report 2020	PU
11/09/20	Fusen Pharmaceutical : Next Day Disclosure Return	PU
13/08/20	Fusen Pharmaceutical : APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR	PU

Fusen Pharmaceutical Company Limited Stock

Stocks

1652

KYG370981030

Pharmaceuticals

Valuation: Fusen Pharmaceutical Company Limited

Chart: Fusen Pharmaceutical Company Limited

Latest news : Fusen Pharmaceutical Company Limited

Press Releases: Fusen Pharmaceutical Company Limited

Quotes and Performance

Course Extremes

Managers and Directors: Fusen Pharmaceutical Company Limited

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-4.85%
1 week	-6.67%
Current month	-9.26%
1 month	-5.77%
3 months	-21.60%
6 months	+27.27%
Current year	+22.50%

1 week	0.91	1.05
1 month	0.91	1.12
Current year	0.68	1.44
1 year	0.3	1.75
3 years	0.24	1.75
5 years	0.24	3.48
10 years	0.24	20

Manager	Title	Age	Since
Zhen Li DFI	Director of Finance/CFO	48	18/04/2019
Zhi Ming Cao IRC	Investor Relations Contact	40	18/01/2013
Yuk Hong Yeung SEC	Corporate Secretary	36	30/09/2024

Director	Title	Age	Since
Tai Sheng Hou BRD	Director/Board Member	63	07/04/2017
Yong Sheng Chi BRD	Director/Board Member	64	07/04/2017
Qing Fen Meng BRD	Director/Board Member	61	07/04/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/04/24	Chang Cheng Cao	Other	Chairman	650,000	0.0867%
18/04/24	Zhi Ming Cao	Other	Chairman	240,000	0.0320%
18/04/24	Chang Cheng Cao	Other	Chairman	240,000	0.0320%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FUSEN PHARMACEUTICAL COMPANY LIMITED	-4.85%	-6.67%	+196.97%	-24.62%	97.2M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.39%	+1.23%	+9.59%	+80.52%	45.7B
OTSUKA HOLDINGS CO., LTD.	+2.03%	+2.97%	+46.99%	+92.04%	34B
CIPLA LIMITED	-2.00%	-2.25%	-10.48%	+33.10%	11.73B
ZYDUS LIFESCIENCES LIMITED	-1.78%	-3.58%	+10.58%	+91.10%	11.48B
KRKA, D. D.	+1.23%	+3.12%	+39.68%	+130.57%	9.28B
GEDEON RICHTER	-0.08%	+0.68%	+17.71%	+42.51%	7.21B
ONO PHARMACEUTICAL CO., LTD.	-0.42%	+1.15%	+43.74%	-18.24%	6.62B
GLENMARK PHARMACEUTICALS LIMITED	-0.83%	-0.26%	+29.37%	+233.98%	6.44B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-3.10%	-3.56%	-43.65%	-7.24%	5.01B
Average	-0.94%	-0.36%	+34.05%	+65.37%	13.76B
Weighted average by Cap.	+0.23%	-0.38%	+20.42%	+80.75%

	2024	2025
Net sales	326M 378M 48.23M 41.56M 38.27M 35.94M 67.47M 4.56B 68.18M 452M 176M 2.23B 181M 177M 7.74B	273M 317M 40.44M 34.85M 32.09M 30.13M 56.57M 3.82B 57.17M 379M 148M 1.87B 152M 149M 6.49B
Net income	-189M -219M -27.93M -24.07M -22.16M -20.81M -39.07M -2.64B -39.48M -262M -102M -1.29B -105M -103M -4.48B	-11.78M -13.66M -1.74M -1.5M -1.38M -1.3M -2.44M -165M -2.46M -16.35M -6.37M -80.71M -6.54M -6.4M -280M
Net Debt	367M 426M 54.33M 46.82M 43.11M 40.48M 76M 5.14B 76.8M 509M 198M 2.52B 204M 200M 8.72B	222M 257M 32.84M 28.3M 26.06M 24.47M 45.94M 3.1B 46.42M 308M 120M 1.52B 123M 121M 5.27B